2024
Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy
Han R, Rao X, Zhou H, Lu L. Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy. International Journal Of Nanomedicine 2024, 19: 4803-4834. PMID: 38828205, PMCID: PMC11144010, DOI: 10.2147/ijn.s461289.Peer-Reviewed Original ResearchConceptsRegulate PD-L1 expressionPD-L1 expressionPD-1/PD-L1Inhibition therapySensitive to immune checkpoint inhibitorsEfficacy of cancer immunotherapyPD-1/PD-L1 inhibitorsImmune checkpoint inhibitorsAnti-cancer immunityEfficacy of monotherapyExploration of combination strategiesModulate immune responsesMRNA vaccine technologyCheckpoint inhibitorsCancer immunotherapyRNA-based therapiesTreatment strategiesImmunomodulatory effectsCancer therapyImmune responseTherapyCancer treatmentVaccine technologyCombination strategiesCancer
2023
Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment
Han R, Wang Y, Lu L. Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment. Pharmaceutics 2023, 16: 59. PMID: 38258070, PMCID: PMC10821464, DOI: 10.3390/pharmaceutics16010059.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsMRNA vaccinesCheckpoint inhibitorsHCC treatmentEffectiveness of mRNAMRNA cancer vaccinesNovel mRNA vaccineSuppressive tumor microenvironmentHepatocellular carcinoma patientsCancer-associated antigensInnovative therapeutic strategiesCOVID-19 preventionCarcinoma patientsVaccine delivery vehiclesCancer vaccinesClinical evidenceHCC preventionTherapeutic strategiesVaccineTumor microenvironmentCancer treatmentPotential targetNew hopeTreatmentTrialsMicroRNAs with Multiple Targets of Immune Checkpoints, as a Potential Sensitizer for Immune Checkpoint Inhibitors in Breast Cancer Treatment
Zhou H, Jia W, Lu L, Han R. MicroRNAs with Multiple Targets of Immune Checkpoints, as a Potential Sensitizer for Immune Checkpoint Inhibitors in Breast Cancer Treatment. Cancers 2023, 15: 824. PMID: 36765782, PMCID: PMC9913694, DOI: 10.3390/cancers15030824.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsImmune checkpoint blockadeBreast cancerCheckpoint inhibitorsCheckpoint moleculesImmune checkpointsImmune checkpoint moleculesCancer-associated mortalityBreast cancer treatmentCommon cancer typesCombination regimenAdverse eventsCheckpoint blockadeClinical benefitTherapeutic effectTherapeutic candidateTherapeutic potentialCancer typesCancerCancer treatmentApplication of miRNAsTargetScan databaseMiRNA therapyTreatmentInhibitors
2022
Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors
Chen Q, Lu L, Ma W. Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors. Cancers 2022, 14: 5983. PMID: 36497465, PMCID: PMC9739567, DOI: 10.3390/cancers14235983.Peer-Reviewed Original ResearchCAR T-cell therapyT-cell therapyCAR T cellsT cellsSolid tumorsChimeric antigen receptor T-cell therapyAdequate T-cell responsesCytokine release syndromeHalf of patientsT cell responsesTumor antigen targetsRelease syndromeAdoptive immunotherapyClinical efficacyHeterogeneous solid tumorsHematological malignanciesSide effectsTarget antigenAntigen targetsTherapyTumorsCancer treatmentNon-cancer cellsCancer cellsEfficacy
2009
Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II
Lu L, Katsaros D, Shaverdashvili K, Qian B, Wu Y, de la Longrais IA, Preti M, Menato G, Yu H. Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II. European Journal Of Cancer 2009, 45: 2212-2218. PMID: 19477633, DOI: 10.1016/j.ejca.2009.05.003.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerIGF-II expressionIGF-IIOvarian cancerPrimary epithelial ovarian cancerInsulin-like growth factor IIUnfavourable prognostic markerOvarian cancer progressionPotential therapeutic targetLin-28BGrowth factor IIStem cellsIGFBP-3Overall survivalDisease progressionPrognostic markerDisease outcomeDisease featuresTherapeutic targetTumor growthTumor samplesFactor IICancer treatmentCancer progressionGrowth factor
2007
Expression of MDR1 in epithelial ovarian cancer and its association with disease progression.
Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Puopolo M, Yu H. Expression of MDR1 in epithelial ovarian cancer and its association with disease progression. Oncology Research Featuring Preclinical And Clinical Cancer Therapeutics 2007, 16: 395-403. PMID: 17913048, DOI: 10.3727/000000006783980892.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsATP Binding Cassette Transporter, Subfamily B, Member 1Biomarkers, TumorBRCA1 ProteinCyclin-Dependent Kinase Inhibitor p16Disease ProgressionDrug Resistance, MultipleEstrogen Receptor alphaFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IIMiddle AgedNeoplasm StagingNeoplasms, Cystic, Mucinous, and SerousOvarian NeoplasmsPrognosisRetrospective StudiesReverse Transcriptase Polymerase Chain ReactionRNA, MessengerRNA, NeoplasmSurvival AnalysisTreatment OutcomeConceptsMDR1 expressionClinicopathological parametersDisease progressionOvarian cancer cohortEpithelial ovarian cancerOvarian cancer prognosisOvarian cancer treatmentOvarian cancer progressionExpression of MDR1Ovarian tumor samplesOverall survivalPatient ageOvarian tumorsIGF-IIQuantitative real-time PCROvarian cancerCancer cohortReal-time PCRIndependent markerCancer prognosisDrug resistanceTumor samplesCancer treatmentCancer progressionERalpha